Aspire Biopharma Holdings (ASBP) Net Income towards Common Stockholders (2021 - 2026)
Aspire Biopharma Holdings' (ASBP) quarterly Net Income towards Common Stockholders came in at -$1.3 million in Q2 2026, up 35.99% year-over-year from -$932497.0 in Q2 2025, and up 60.65% quarter-over-quarter from -$3.2 million in Q1 2026.
Powered by 
Analysis
Aspire Biopharma Holdings (ASBP) Net Income towards Common Stockholders (2021 - 2026) Analysis & Trends
Aspire Biopharma Holdings (ASBP) has reported Net Income towards Common Stockholders for 6 consecutive years, with -$1.3 million the latest figure, recorded in Q2 2026.
- On a quarterly basis, Net Income towards Common Stockholders rose 35.99% year-over-year to -$1.3 million in Q2 2026; TTM through Jun 2026 was -$15.2 million, a 19.18% increase from a year earlier, with the FY2025 full-year figure at -$19.3 million, down 54.26% from the prior year.
- Net Income towards Common Stockholders was -$1.3 million for Q2 2026 at Aspire Biopharma Holdings, up from -$3.2 million in the prior quarter.
- Over five years, Net Income towards Common Stockholders peaked at $2.3 million in Q1 2023 and troughed at -$15.9 million in Q1 2025.
- A 5-year average of -$1.7 million and a median of -$409263.5 in 2024 frame the typical range for Net Income towards Common Stockholders.
- Across the five-year window, Net Income towards Common Stockholders soared 230057.35% in 2022 and sank 1493.23% in 2024, its largest moves.
- Over 5 years, Net Income towards Common Stockholders stood at $1.7 million in 2022, then slumped by 102.41% to -$41910.0 in 2023, then slumped by 1493.23% to -$667722.0 in 2024, then tumbled by 1110.51% to -$8.1 million in 2025, then jumped by 84.31% to -$1.3 million in 2026.
- The last three Net Income towards Common Stockholders figures came in at -$1.3 million (Q2 2026), -$3.2 million (Q1 2026), and -$8.1 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 208.48 Bn | 194.49 Bn | 7.24 Bn | 2.38 Bn |
| 2 | Gilead Sciences | 186.29 Bn | 183.02 Bn | 6.22 Bn | -10.50 Bn |
| 3 | Vertex Pharmaceuticals | 128.79 Bn | 120.93 Bn | 2.84 Bn | 1.10 Bn |
| 4 | Regeneron Pharmaceuticals | 80.66 Bn | 72.67 Bn | 3.93 Bn | 1.30 Bn |
| 5 | Moderna | 61.46 Bn | 56.32 Bn | 52.00 Mn | -782.00 Mn |
| 6 | Argenx Se | 61.28 Bn | 56.10 Bn | 1.37 Bn | 472.00 Mn |
| 7 | Alnylam Pharmaceuticals | 32.04 Bn | 28.73 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Biogen | 31.84 Bn | 30.56 Bn | 1.96 Bn | 97.50 Mn |
| 9 | Roivant Sciences | 28.74 Bn | 29.43 Bn | 1.16 Mn | -290.61 Mn |
| 10 | Aspire Biopharma Holdings | 64.13 Mn | 51.96 Mn | -30,086.00 | -1.27 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -1.27 Mn |
| Mar 31, 2026 | -3.22 Mn |
| Dec 31, 2025 | -8.08 Mn |
| Sep 30, 2025 | -2.63 Mn |
| Jun 30, 2025 | -1.98 Mn |
| Mar 31, 2025 | -15.94 Mn |
| Dec 31, 2024 | -667,722.00 |
| Sep 30, 2024 | -216,269.00 |
| Jun 30, 2024 | -602,258.00 |
| Mar 31, 2024 | -2.47 Mn |
| Dec 31, 2023 | -41,910.00 |
| Sep 30, 2023 | -69,258.00 |
| Jun 30, 2023 | 1.47 Mn |
| Mar 31, 2023 | 2.30 Mn |
| Dec 31, 2022 | 1.74 Mn |
| Sep 30, 2022 | 861,773.00 |
| Jun 30, 2022 | 96,554.00 |
| Mar 31, 2022 | -45,819.00 |
| Dec 31, 2021 | -755.00 |
| Sep 30, 2021 | -15,310.00 |